Stay updated with breaking news from Athersys Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- The cell therapy market size is expected to grow by USD 31.04 billion from 2022 to 2027. In addition, the momentum of the market will progress...
The cell therapy market size is expected to grow by USD 31.04 billion from 2022 to 2027. In addition, the momentum of the market will progress at a CAGR of 57.06% during the forecast period, according to Technavio Research. The market has been segmented by type (autologous and allogenic), application (malignancies, musculoskeletal, cardiovascular, and others), and geography (North America, Europe, Asia, and the Rest of the World (ROW)). North America accounts for 40% of the growth of the global
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces changes to its Board of Directors following the Company’s recent 2023 Annual Meeting of Stockholders. Current Director Jane Wasman, JD, has been ap...
Athersys, Inc. , a regenerative medicine company developing MultiStem® for critical care indications, announces changes to its Board of Directors following the Company’s recent 2023 Annual...
StockNews.com began coverage on shares of Athersys (NASDAQ:ATHX – Free Report) in a report published on Sunday morning. The firm issued a hold rating on the biopharmaceutical company’s stock. Athersys Price Performance Shares of Athersys stock opened at $0.31 on Friday. Athersys has a one year low of $0.26 and a one year high of […]